RT Journal Article
SR Electronic
T1 Evaluation of the diagnostic value of YiDiXie™-SS in breast ultrasound-positive patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.02.24309738
DO 10.1101/2024.07.02.24309738
A1 Wu, Yutong
A1 Zhou, Huimei
A1 Li, Xutai
A1 Sun, Chen
A1 Ge, Zhenjian
A1 Chen, Wenkang
A1 Li, Yingqi
A1 Lin, Shengjie
A1 Zhang, Pengwu
A1 Wang, Wuping
A1 Chen, Siwei
A1 Li, Wei
A1 Han, Yanni
A1 Hu, Hui
A1 Liu, Xiaoling
A1 Lai, Yongqing
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309738.abstract
AB Background Breast cancer is a serious threat to women’s health and breast cancer screening is of great importance. Ultrasound scan is widely used for screening or preliminary diagnosis of breast tumors, but its large number of false-positive results brings unnecessary mental pain, expensive examination costs, physical injury and other adverse consequences. There is an urgent need to find a convenient, cost-effective and noninvasive method to reduce the false-positive rate of breast ultrasound. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS in breast ultrasound-positive patients.Patients and methods 134 subjects (malignant group, n=96; benign tumor group, n=38) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS were evaluated respectively.Results The sensitivity of YiDiXie ™ -SS in the malignant group was 97.9%(95% CI: 92.7% - 99.6%; 94/96) with a false negative rate of 2.1%(95% CI: 0.4% - 7.3%;2/96). The specificity of YiDiXie™-SS for the benign group was 63.2%(95% CI: 47.3% - 76.6%; 24/38), and the false positive rate was 36.8%(95% CI: 23.4% - 52.7%; 14/38) . This means that YiDiXie™-SS reduces the false positive rate by 63.2%(95% CI: 47.3% - 76.6%; 24/38) with essentially no increase in malignancy leakage.Conclusion YiDiXie ™ -SS significantly reduces the false-positive rate of breast ultrasound-positive patients without increasing the number of under-diagnosed malignant tumors. YiDiXie ™ -SS has vital diagnostic value in breast ultrasound-positive patients, and is expected to solve the problem of “high false-positive rate of breast ultrasound”.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200066840Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.